Molecularly targeted endocrine therapies for breast cancer

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Orlando, L ^a   Schiavone, P ^a   Fedele, P ^a   Calvani, N ^a   Nacci, A ^a   Rizzo, P ^a   Marino, A ^a   D'Amico, M ^a   Sponziello, F ^a   Mazzoni, E ^a   Cinefra, M ^a   Fazio, N ^b   Maiello, E ^c   Silvestris, N ^d   Colucci, G ^d   Cinieri, S ^a,b  

^a A Perrino Hospital   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c Casa Sollievo Della Sofferenza   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Endocrine therapy; Estrogen receptor signalling; Growth factor signalling

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; MEGESTROL ACETATE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DEGRADATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; MOLECULARLY TARGETED THERAPY; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECURRENCE RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR CELL; VISCERAL METASTASIS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 78649735494     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70023-2     Document Type: Article

References (40)

1. Osborne CK Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23:1616-1622.
2. Osborne CK, Schiff R Aromatase inhibitors: future directions. J Steroids Biochem Mol Biol 2005, 95:183-187.
3. Dowsett M, Allred C, Quinn E, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26(7):1059-1065.
4. Maehle BO, Collette K, Tretli S, et al. Estrogen receptor beta - an independent prognostic marker in ER alpha and progesterone receptor-positive breast cancer?. APMIS 2009, 117(9):644-650.
5. Fox EM, Davis RJ, Shupnik MA ERb in breast cancer - outlooker, passive player, or active protector?. Steroids 2008, 73(11):1039-1051.
6. Silva E, Kabil A, Kortenkamp A Cross-talk between non-genomic and genomic signalling pathways - distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol 2010, 245(2):160-170.
7. Cato AC, Nestl A, Mink S Rapid actions of steroids receptors in cellular signalling pathways. Sci STKE 2002, (138):re9.
8. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trial. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
9. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001, 93:684-690.
10. Osborne CK Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618.
11. Riggs L, Hartmann LC Selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med 2003, 348:618-629.
12. Nilsson S, Koehler KF Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol 2005, 96:15-25.
13. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifen: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifen Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
14. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Adjuvant Breast and Bowel Project study of tamoxifen and raloxifen (STAR) P-2 trial: Preventing breast cancer. Cancer Prev Res 2010, 3(6):696-706.
15. Wakeling AE, Dukes M, Bowler J A potent specific pure antioestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
16. Dauvois S, Danielian PS, White R, et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. PNAS 1192;89:4037-41.
17. Robertson JFR, Osborne R, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
18. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, doubleblind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
19. Robertson JFR, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009, 27(27):4530-4535.
20. Maurian L, Romieu G, Bines J Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastasis: data from EFECT trial. Breast Cancer Res Treat 2009, 117(1):69-75.
21. Buzdar AU Advanced in endocrine treatment for postmenopausal women with metastatic and early breast cancer. Oncologist 2003, 8:335-341.
22. ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, alone or in Combination) trial after completion of 5 years of adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
23. A comparison of letrozole and tamoxifen in post menopausal women with early breast cancer. N Engl J Med 2005, 3533:2747-2757. The Breast Intergroup 1-98 Collaborative Group.
24. Coombes RT, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
25. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl 7):vii10-vii14.
26. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366(9484):455-462.
27. Obsborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator A1B1 (SRC3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003, 95:353-361.
28. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006, 24:3019-3025.
29. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11:4741-4748.
30. Shou J, Massarweh S, Osborne CK, et al. Mechanism of tamoxifen resistance: increased estrogen-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004, 96:926-935.
31. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/Erb receptors. Mol Cell 2003, 12:541-552.
32. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-27neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
33. Ali S, Metzger D, Bornert JM, et al. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO 1993, 12:1153-1160.
34. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27(33):5529-5537.
35. Osborne K, Neven P, Dirix K, et al. Randomized phase II study of gefitinib (IRESSA) or placebo in combination with tamoxifen in patients with hormone receptor positive metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):S107.
36. Cristofanilli M, Valero V, Mangalik A, et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16(6):1904-1914.
37. Schwartzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as firstline therapy of Her-2 + hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15(2):122-129.
38. Miller WR Identification and mechanisms of endocrine resistance. Breast Cancer Res 2008, 10(Suppl 4):10.
39. Sabnis G, Brodie A Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clin Breast Cancer 2010, 10(1):E6-15.
40. Lewis JS, Cheng D, Jordan VC Targeting oestrogen to kill the cancer but not the patient. Br J Cancer 2004, 90:944-949.